	,			The state of the s
ork Reduction Act of	if 1995, no persons as	e required to respond to a collection of information u	redrnun fortnoo BMO bilav a aristnoo ii azean	
Substitute fo	r form 1449A	РТО	Con	nplet if Kn wn
ST	ATEMEN	T BY APPLICANT	Applicati n Number	Divisi nal <i>e</i> 1 09/718,693
	(,,	Filing Date	August 22, 2003
			First Named Inventor	John B. Hartey
			Group Art Unit	
			Examiner Name	
1	of	15	Attorney Docket Number	OMRF 177 DIV
	Substitute fo INF STA	INFORMATI STATEMEN (use as many	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Filing Date First Named Inventor Group Art Unit Examiner Name

			U.S. PATENT DOCUM	ENTS	
Examiner Initials*	Cite US Patent Document No.1		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	Number Kind Code (if known	n)			
135		4,244,946	Rivier, et al.	01-13-1981	
		4,305,872	Johnston, et al.	12-15-1981	
		4,316,891	Guillemin, et al.	02-23-1982	
		4,675,382	Murphy	06-23-1987	
		4,792,525	Ruoslahti, et al.	12-20-1988	
		5,637,454	Harley	06-10-1997	
V		5,906,820	Bacha	05-25-1999	
		ļ			
		 			
					-

				FC	DREIGN PATENT DOCUMEN	ITS .		
Examiner Cite Initials* No.1	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te	
		Office.3	Number*	Kind Code ³ (if known)	•	1	•	
A		PCT	WO 98/30586		Oklahoma Medical Research Foundation	07-16-1998		
As		PCT	WO 99/02550		Queensland Institute for Medical Research	01-21-1999		
		-		 	 -			
				+				
		<u> </u>						1

		·	
Examine Signature	\sim	Date Considered 8/	5/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁶ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please	Non a	nè e cia	n (4) in	cirlo this	hox 🛶
L 40476	4200	Mary 194	M (4) 24	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	

Sheet

PTO/SB08A (10-86
Approved for use through 10/31/99. OMB 0551-0031
Patant and Trademark Office: U.S. DEPARTMENT OF COMMERCE

OMRF 177 DIV

815105

Substitute for form 1449A/PTO		Complet If Kn wn
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Applicati n Number	Divisi nal ef 09/718,693
(555 45 112) 51.555 45 1555552.	Filing Date	August 22, 2003
	First Named Inventor	John B. Harley
	Group Art Unit	

Examiner Name
Attorney Docket Number

15

F	014-	OTHER ART - NON PATENT LITERATURE DOCUMENTS						
Examiner's Cite Initials* No.								
AS		ADELSTEIN, et al., Nucl. Med. Biol. 14: 165-169 (1987).						
		ALFORD, Antiviral agents and viral diseases of man 2 rd ed. Raven Press: New York, pp. 433-86 (1984).						
		ALSBAUGH, et al., Arthr. Rheum. 19: 711-719 (1976).						
		ALSBAUGH, et al., <i>J. Clin. Invest.</i> 67: 1134-1140 (1981).						
		ASHLEY, et al., "Detection of asymptomatic herpes simplex virus infections after vaccination," J. Virol. 61: 253-258 (1987).						
		BABCOCK, et al., <i>J. Exp. Med.</i> 190: 567-576 (1999).						
		BARNES, <i>Pharma Weekly</i> 1: 11 (1995).						
+ +		BELL, et al., <i>J. Rheumalol.</i> 11: 277-281 (1984).	_					
-		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," Arch. Neurol. 42: 1798-1804 (1992).						
		BRAY, et al., Arch. Neurol. 40: 406-408 (1983).						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Examiner's

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English tanguage Translation is attached.

Please to	roe e ob	s sion (+	l insida	this hor	_

	PĪ	O/SBO8A	(10-96
Approved for use through	10/31/99.	OMB 065	1-0031
Palent and Trademark Office: U.S. DEPA	THEMTR	OF COM	FRCE

					Peters and Transment Order, U.S. DEPARTMENT OF COMMERC
Under the Pay	Substitute fo			formation unless it contains a valid OMB control number	ompi t if Kn wn
	STAT	EMENT	N DISCLOSURE BY APPLICANT heets as necessary)	Applicati n Number	Divisi nal of 09/718,693
ļ	last	ous many s	needs as necessary)	Filing Date	August 22, 2003
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	3	of	15	Attorney Docket Number	OMRF 177 DIV

Examiners	Cite	OTHER ART NON PATENT LITERATURE DOCUMENTS						
Initials* No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T					
A		BROWNING, et al., <i>J. Immunol.</i> 143: 1859-1867 (1989).						
		CALDERWOOD, et al., "Nucleotide sequence of the Shiga-like toxin genes of Escherichia coli," Proc. Natl. Acad. Sci. USA 84: 4364-4368 (1987).	 					
		CATALANO, et al., "Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis," Proc. Natl. Acad. Sci USA 76: 5825-5828 (1979).						
	_	CHEN, et al., <i>J. Biol. Chem.</i> 266: 18237-18243 (1991).						
		COLOMBATTI, et al., <i>J. Biol. Chem.</i> 261: 3030-3035 (1986).	ļ					
		DALLDORF, et al., "The Lymphomas of Brazilian Children," J. Am. Med. Assn. 208: 1365-8 (1969).	+					
	·	DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163: 351-360 (1991).	<u> </u>					
		DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," Am J. Med. 92: 453-454 (1992).	-					
		DEBRUS, et al., "Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency," J. Virol. 69: 3240-3245 (1995).						
1/1		DEDRICK, et al., Cancer Treat. Rep. 62: 1-11 (1978).						

Constant			
Examiners		Date Considered	0.41 -
Signature	/		X/5/25
			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please type a	nius sion (el inside	this box →

PTO/SBO8A (1)	>9 6
Approved for use through 10/31/99. QMB 0651-0	
Patent and Trademark Office: U.S. DEPARTMENT OF COMMER	ICF.

		of 1995, no persons at or form 1449A		ormation unless it contains a valid CMB control number		
		•		. C	omplete if Kn wn	
			N DISCLOSURE BY APPLICANT	Applicati n Number	Divisi nal of 09/718,693	
	(us	e as many she	eets as necessary)			
				Filing Date First Named Inventor	August 22, 2003	
				Group Art Unit	John B. Harley	
				Examiner Name		·
Sheet	4	of	15	Attorney Docket Number	OMRF 177 DIV	
· · · · ·			 			
				NON PATENT LITERATURE DOCUM		
Examiner's Initials*	Cite No. ¹	; i	item (book, magazine, journal	(in CAPITAL LETTERS), title of the article, , serial, symposium, catalog, etc.), date, problisher, city and/or country where publish	age(s), volume-Issue number(s),	T
DELEERS, et al., FEBS Lett. 160: 82-86 (1983).						
	DIENER, et al., "Specific Immunosuppression by Immunotoxins Containing Daunomycin," Science 231(4734): 148-150 (1986).					
	DIGARD, et al., "Functional analysis of the herpes simplex virus UL42 protein," J. Virol. 67: 1159-1168 (1993).					
	ДІП	MER, et al., "A c	luster of latently expressed ger	es in Kaposi's sarcoma-associated herpesvi	rus," J. Virol. 72: 8309-8315 (1998).	
	DON	AHUE, et al., Arc	ch. Int. Med. 155: 1605-1609 (1	995).		
	ELEK	, et al., <i>Lancet</i> 1	: 1-5 (1974).			
					•	
	ERTL, et al., "Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells," J. Virol. 66: 4126-33 (1992).					
	FERREL, et al., J. Clin. Invest. 67: 681-687 (1981).					
	FINE! Major	RTY, et al., "Imm Viral Envelope (nunization of Cottontop Tamarin Glycoprotein gp340 and Alum,	is and Rabbits with a Candidate Vaccine Agi Vaccine 12: 1180-1184 (1994).	ainst the Epstein-Barr Virus Based on the	
	FINEI głycoj	RTY, et al., "Prot protein gp340 Pr	tective Immunization Against E roduced from a Bovine Papillor	ostein-Barr Virus-Induced Disease in Cottont mavirus Expression Vector,* <i>J. Gen. Virol.</i> 73	top Tamarins Using the Virus Envelope s: 449-453 (1992).	
Examiner's Signature	1	^		Date Consid	ered 8/5/05	•

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Classes N	ma a mba	circ (a)	inside this	here
11B3338 0	roe a caus	500110	1209 AI2	DU

PTOSBOBA (10-9
Approved for use through 10/31/99, CNIB 0651-003
Puters and Trademark Office: U.S. DEPARTMENT OF COMMERC

Substitute for form 1449A/PTO			PTO	Complet If Kn wn		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Applicati n Number	Divisi nal 1 09/718,693	
	•	•		Filing Date	August 22, 2003	
				First Named Inventor	John B. Harley	
				Group Art Unit		
				Examiner Name		
heet	5	of	15	Attorney Docket Number	OMRF 177 DIV	

		OTHER ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials* -	Cite No.	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
A		FOX, "Sjogren's Syndrome," Current Opin. Rheum. 7: 409-416 (1995).	
		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," J. Immunol. 137: 3162-3168 (1986).	
		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," J. Rheumatol. 19: 18-24 (1992).	
		GLASSY, et al., <i>J. Immunol. Methods</i> 81: 115 (1985).	
		GOODRICH, et al., Ann. Intern. Med. 118:173-178 (1993).	
		GRAY, et al., "Cloning, nucleotide sequence, and expression in Escherichia coli of the exotoxin A structural gene of Pseudomonas aeruginosa," Proc. Natl. Acad. Sci. USA 81: 2645-2649 (1984).	
		GREENWOOD, et al., <i>Biochem. J.</i> 89: 114-123 (1963).	
		GRIFFITHS, et al., Cancer Res. 51: 4594-4602 (1991).	
		GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84: 171-177 (1995).	
		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," Cancer Res. 56: 969-972 (1996).	

Examiner's Date Considered 5/5/55			
	(Examiner's		Date Considered / / - ' /
	Signature	· · · · · · · · · · · · · · · · · · ·	\$ / \ / \ Z
	Olghaloic	<u> </u>	

+

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

	,,,				Approved for use through 1001/99, OMB Patent and Trademark Office: U.S. DEPARTMENT OF OR	OSSÍOCO DMINERCE
		ction Act of 1995, no persons an tutte for form 1449A/		britation unless it contains a valid OMB control number	complet if Kn wn	<u> </u>
			I DISCLOSURE BY APPLICANT	Applicati n Numb r	Divisi nal 109/718,693	
ļ		(use as many she	eets as necessary)			
 .				Filing Date First Named Inventor	August 22, 2003	
l				Group Art Unit	John B. Harley	·
ļ				Examiner Name		
Sheet I		6 01	15	Attorney Docket Number	OMRF 177 DIV	
0001				Attenticy booket Humber	Olinii 177 Dit	
			OTHER ART I	NON PATENT LITERATURE DOCUM	MENTS	
Examiner's Initials*	Cite No.1	1	tem (book, magazine, journal	(in CAPITAL LETTERS), title of the article i, serial, symposium, catalog, etc.), date, p publisher, city and/or country where publis	age(s), volume-issue number(s), hed	T
P	HAAHR, et al., "A Putative New Retrovirus Associa Disease," Ann. N. Y. Acad. Sci. 724: 148-156 (1996)				nvolvement of Epstein-Barr Virus In This	
		HALPERN, et al., J. N.	ucl. Med. 29: 1688-1696 (1986	3).		
		HARLEY & JAMES, "E Arthr. Rheum. 42(8): 1	pstein-Barr virus infection ma 782-1783 (1999).	y be an environmental risk factor for systemi	c lupus erythematosus in children and teenagers,"	<u> </u>
		HESLOP, et al., *Long Specific T Lymphocyte	Term Restoration of Immunity es," Nature Med. 2: 551-555 (1	/ Against Epstein-Barr Virus Infection by Add 996).	optive Transfer of Gene-Modified Virus-	
		HISKEY, Peptides 3: 1	37 (1981).			
		HO, <u>Cytomegalovirus</u>	biology and infection: current	topics in infectious disease Plenum Press: N	lew York, pp. 105-118 (1982).	
		HOCH, et al., "Channe membranes," Proc. Na	els formed by botulinum, tetanu atl. Acad. Sci. USA 82: 1692-10	us, and diphtheria toxins in planar lipid bilaye 696 (1985).	ers: relevance to translocation of proteins across	
		HWANG, et al., Cell 48	3: 129-136 (1987).			
		INOUE, et al., "Analys Rheumatoid Arthritis,"	sis of Antibody Titers to Epsteli J. Infect. Dis. 164: 22-28 (199	n-Barr Virus Nuclear Antigens in Sera of Pati 11).	ients with Sjogren's Syndrome and with	
/		ISHII, et al., *Cyclohex 73: 463-468 (1995).	imide-Induced Apoptosis in Bu	rkitt Lymphoma (BJA-B) Cells with and With	out Epstein-Barr Virus Infection," Immunol. Cell Biol.	

Examiner's	. /	Date Considered	0.1/1
Signature			¥ /5 /05
Organization			

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

•	Pī	O/SBOBA	(10-96
Approved for use through 10/3:	L/99.	CAUB OSS	1-0031
laters and Trademark Office: U.S. DEPARTM	ENT	OF COM	IFRCE

Substitute for form 1449A/PTO	C	omplet if Kn wn
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Divisi nat 1 09/718,693
(Coo as many shoots as necessary)	Filing Date	August 22, 2003
	First Named Inventor	John B. Harley
	Group Art Unit	
	Examiner Name	
7 of 15	Attorney Docket Number	OMRF 177 DIV

Examiners I	Cite	OTHER ART NON PATENT LITERATURE DOCUMENTS
Initials*	No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
A		JAMES & HARLEY, *Linear Epitope Mapping of an Sm B/B' Polypeptide," J. Immunol. 148: 2074-2079 (1992).
		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/8'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," J. Exp. Med. 181: 453-461 (1995).
		JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," J. Clin. Invest. 100: 3019-26 (1997).
		JAMES, et al., Anhr. Rheum. 41: S308 (1998).
		JI, Meth. Enzymol. 91: 580-609 (1983).
		KAHAN, et al., <i>Arthr. Rheum.</i> 28: 961-70 (1985).
		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an in situ Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," Clin. Exp. Rheum. 10: 327-332 (1992).
71		KHANNA, et al., "Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies," J Virology 70(8): 5357-5362 (1996).
1		KIMURA, et al., <i>Clin. Exp. Immunol.</i> 103: 192-298 (1996).
1/		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Enythematosus," Immunol. Lett. 17:249-252 (1988).

Signature	Date Considered 8/5/65	
		_

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

(Boses		 fit balds	this hor -
1,0022	ODS I	14) 0300	0.6 000

PTO/SBOSA (10-S	26
Approved for use through 10/31/99. OMB 0651-003	51
Bled and Trademak Office: II S DEPARTMENT OF COLUMN	_

4	۰	•

						Approved for use through 10/31/99. Patent and Trademark Office: U.S. DEPARTMENT (OMB 0551-00 OF COMMERC
Under the Peperwork	Reduction Act of	of 1995, no person	ns are required to	to respond to a collection of in	information untess it contains a valid OMB control number	er .	
	Summe ide	/ IOIIII 1990	3AC 10			Complet If Kn wn	
	STATE	EMENT	T BY A	CLOSURE PPLICANT	Application Number	Divisi nal 109/718,693	
ļ		as many a	310013 23	ribcosary,	Filing Date	August 22, 2003	
					First Named Inventor	John B. Harley	
					Group Art Unit	Doini D. Hailey	
					Examiner Name		
Sheet	8	of	T	15	Attorney Docket Number	OMRF 177 DIV	
				OTHER ART -	NON PATENT LITERATURE DO	CUMENTS	
	ite lo.¹		item (box	name of the author ok, magazine, journa	(in CAPITAL LETTERS), title of the and il, serial, symposium, catalog, etc.), dat publisher, city and/or country where pu	ticle (when appropriate), title of the	77
A	KOHLE	ER & MILSTE	EIN, Eur. J.	256: 495-497 (1975) Immunol. 6: 511-519	(1976).	·	
	KOIDE Virol. 7	, et al., "Spo 71: 2478-248	ntaneous es 11 (1997).	stablishment of an Ep	stein-Barr virus-infected fibroblast line fro	om the synovial tissue of a meumatoid arthritis patient,"	J.
	KOND	NAMAY & C	ISHI, <i>24</i> ° In	itemational Herpesvin	us Workshop, July 17-23 (Mass. Inst. Tec	ch.) Abst. 1.016 (1999).	+
	KOND	O et al., "Hu	man cyfomr	enalovinus latent nene	overecian in ampuloado marcobara	progenitors in culture and in seropositive individuals."	
	Proc. N	lati. Acad. So	d. USA 93:	11137-1142 (1996).	техртеssion ит grandiocyte-macrophage (progenitors in culture and in seropositive individuals,"	
	KOYAN	AA, et al., Ch	nem. Abstr.	120: 217-262 (1994).			+-
	KRAUS	E & STRAU	ISS, Infect. I	Dis. Clin. N.A. 13: 61-	81 (1999).		
					· · · · · · · · · · · · · · · · · · ·		
	LARSE	N, et al., *Ep	ostein-Barr I	Nuclear Antigen and \	Viral Capsid Antigen Antibody Titers in M	ultiple Sclerosis," Neurology 35:435-438 (1985).	
	LAZARI Multivis	OVITS, et al. ceral Transp	., "Anti-B Ce plantation," (all Antibodies for the T Clin. Invest. Med. 17:6	realment of Monoclonal Epstein-Barr Vir 321-625 (1994).	us-Induced Lymphoproliferative Syndrome After	+

Examiner's Signature	~	Date Considered	815/05	
			0/// 4)	

LENNETTE, et al., "Antibodies to LMP2A/2B in EBV-carrying malignancies," Eur. J. Cancer 31(11): 1875-1878 (1995).

^{*}EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please type a	nhis tim (Al inside	this how
Legistro (Line e		77 1 1 1 1 1 1	413 KM -

Sheet

Under the Peperwork Reduction Act of 1995, no persons are required Substitute for form 1449A/PTO

15

PTO/SB08A (10-96

OMRF 177 DIV

. 🗀		Approved to use through 10/31/99. QMB 0651-0031 . Patient and Trademark Office: U.S. DEPARTMENT OF COMMERCE
k Raduction Act of 1995, no persons are required to respond to a collection of int	ormation unless it contains a valid ONB control number	
ubstitute for form 1449A/PTO		
•	·	Complet If Kn wn
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	Divisional 109/718,693
(use as many sheets as necessary)	Filing Date	August 22, 2003
	First Named Inventor	John B. Harley

[OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, calalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Tr
A		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," Nature 375:685-688 (1995).	
		LONGNECKER & KIEFF, "A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1," J. Virol. 64: 2319-2326 (1990).	
		MASSEN, et al., Eur. J. Biochem. 134: 32 (1983).	
		MAHALINGAM, et al., "Expression of protein encoded by Varicella-Zoster virus open reading frame 63 in latently infected human ganglionic neurons," Proc. Nat'l. Acad. Sci., USA 93: 2122-2124 (1996).	
		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," Am. J. Med. 96:97 (1994).	
	-	MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by in Situ Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," Am. J. Med. 90:286-294 (1991).	•
		MARKMAN, Semin. Oncol. 18: 248-254 (1991).	
		MEANS, et al., <u>Chemical modifications of proteins</u> Holden-Day: San Francisco, pp. 105-110 (1971).	
		MEARES, et al., Anal. Biochem. 142: 68-78 (1984).	
		MEIGNER, et al., J. Infect. Dis. 162: 313-321 (1990).	

Group Art Unit Examiner Name Attorney Docket Number

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanesse patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please t	YDS A	nte sim	(4) its	ide	his	hrs

_	PT	D/SBOBA	(10-96
Approved for use through 10/31/	99.	OMB 065	1-0031
Patent and Tradement Office: U.S. DEPARTME	UT	OF COM	EDCC

1	ı		
	Ĺ	_	

					Patent and Trademerk Office: U.S. DEPARTMENT OF	F COMMERC
		uction Act of 1995, no persons itute for form 1449/		information untess à contains a valid OMB control number	omplete if Kn wn	
			ON DISCLOSURE BY APPLICANT	Application Number	Divisi nal f 09/718,693	
		(use as many si	sheets as necessary)	Fille Cate		
				Filing Date First Named Inventor	August 22, 2003	
ĺ		•		Group Art Unit	John B. Harley	
				Examiner Name		
Sheet	1	10 of .	15	Attorney Docket Number	OMRF 177 DIV	
					OBERT 177 OF	
			OTHER ART I	NON PATENT LITERATURE DOCUM	ENTS	
Examiner's Initials*	No.1	1_	Include name of the author (item (book, magazine, journal	(in CAPITAL LETTERS), title of the article (tal., serial, symposium, catalog, etc.), date, page publisher, city and/or country where publish	(when appropriate), title of the age(s), volume-issue number(s).	T
As		MERRIFIELD, J. Am	m. Chem. Soc. 85: 2149 (1964).			+
		MIYASHITA, et al., *	Identification of the site of Epster	eln-Barr virus persistence in vivo as a resting B	3 cell," J. Virol. 71: 4882-4891 (1997).	-
		MOCARSKI, "Cytom	negaloviruses and their replication	on" in <u>Fields Virology,</u> 3 rd ed. (Fields, et al. eds.	.) Lippincott-Raven pp. 2447-2480 (1996).	+
		MORGAN, "Epstein-	-Barr Virus Vaccines," Vaccine 10	0:563-571 (1992).		+
		MORGAN, et al., "Va (1989).	alidation of a First-Generation Ep	pstein-Barr Virus Vaccine Preparation Suitable	of or Human Use," J. Med. Virol. 29:74-78	-
		MORSHED, et al., fr (1992).	ncreased Expression of Epstein-	Barr Virus in Primary Biliary Cirrhosis Patients	s," Gastroenterol. Jpn. 27(6):751-758	
		MUJOO, et al., Onco	ogene 12:1617-1623 (1996).			+
		MUSAINI, et al., Ann	n. Rheum. Dis. 46: 837-42 (1987).	j.		+
		MYERS, et al., J. Imr	nmunol. Meth. 121(1): 129-142 (19	989).		-
		NAKABAYASHI, et a	al., Rheumatol. Int. 5: 61-7 (1985)).		+

Examiner's Signature	~	Date Considered	815/05

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

Please	٠	-4-	ء سند	تسط در	4. 64	h
76834	MDS T	DI.5	550m (4) DS.I		$m \rightarrow$

PT	O/SBO8A	(10-96
Approved for use through 10/31/99.	OMB 065	10031
Palarsi and Tradement Office: U.S. DEPARTMENT	OF COM	1FDCC

					Patent and Tradement Office: U.S. DEPARTMENT OF COMMERC
Under the Par	perwork Reduction Act	of 1996, no persons	s are required to respond to a collection of in	termation unless it contains a valid OMB control number	
1	Substitute fo	r form 1449	A/PTO		
				C	omplete if Kn wn
	INFOR	OITAMS	N DISCLOSURE	Applicati n Numb r	Divisional of 09/718,693
	STAT	EMENT	BY APPLICANT		
l	(use	e as many s	heets as necessary)		
			•	Filing Date	August 22, 2003
	•			First Named Inventor	John B. Harley
l				Group Art Unit	
				Examiner Name	
Sheet	11	of	15	Attorney Docket Number	OMRF 177 DIV

		OTHER ART NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ²
A.		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," Br. J. Rhuem. 33:317-322 (1994).	
		NG, et al., Lancet 1(8166): 447-9 (1980).	
		OI, et al., "Chimeric antibodies," BioTechniques 4(3): 214 (1986).	
		PALLESEN, et al., "Expression of Epstein-Barr Virus Latent Gene Products in Turnor Cells of Hodgkin's Disease," Lancet 337 (8737): 320-322 (1991).	
		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," Ophthalmology 97:976-984 (1990).	
		PFLUGFELDER, et al., "Epstlen-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," Am. J. Pathol. 143:49-64 (1993).	
		PLOTKIN, et al., <i>J. Infect. Dis.</i> 159: 860-565 (1989).	
		PLOTKIN, et al., <i>Infect. Immun.</i> 12: 521-527 (1975).	
11		PLOTKIN, et al., <i>Rev. Infect. Dis.</i> 12: 827-838 (1990).	
		QUADRI, et al., <i>Nucl. Med. Biol.</i> 20: 559-570 (1993).	

Examiner's Signature	\sim	Date Considered 8 /5 /65
*EXAMINER:	Initial if reference considered, whether or not citation is in c	conformance with MPEP 609. Draw line through citation if not in conformance and not considere

Examiners

Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

	PT	0/5B08A	(10-96
Approved for use through 10/31	V99.	ON/B 065	1.0031
Patent and Trademark Office: U.S. DEPARTM	ENT	OF COMM	TERME

	1		
	٠	ŀ	•

					Patent and Trademark Office: U.S. DEPARTMENT OF	FCOMMER
				information unless it contains a valid OMB control number		
	Substitute	for form 1449	9A/PTO	~	omplete if Kn wn	
Ì				_ ~	ompiee ii kn wn	
	INFO	RMATIC	ON DISCLOSURE	Applicati n Number	Divisi nai 109/718,693	
ŀ			BY APPLICANT]		
	• • • • • • • • • • • • • • • • • • • •					
	. (u	se as many s	sheets as necessary)			
				Filing Date	August 22, 2003	
				First Named Inventor	John B. Harley	
			•	Group Art Unit Examiner Name		
Sheet	12	of	15	Attorney Docket Number	OMRF 177 DIV	
				Principles of the state of the	OWNF 177 DIV	
			OTHER ART	NON PATENT LITERATURE DOCUM	ENTS	
Examiner's Initials*	Cite No.1		Include name of the author	(in CAPITAL LETTERS), title of the article (when appropriate), title of the	T
				il, serial, symposium, catalog, etc.), date, pa publisher, city and/or country where publish	ge(s), volume-issue number(s), ed	
	REL	JSSER, et al., J	J. Infect. Dis. 166: 473-479 (1992).		+-
						1
-// -	BIC	KINSON & KIE	FF "Enctoin Ram vinue" in Fields	Virology Lippincott-Raven, pp. 2397-2446 (19		
- 1	"	MINOUN & MILI	rr, cpsteurbairvilus ili <u>rieius</u>	<u>virology</u> Lippincott-Haven, pp. 2397-2446 (19	19 6).	1
l						
	ROI	WELL, et al., "	Site-specific covalent modification	n of monoclonal antibodies: in vitro and in vivo	evaluations,* Proc. Natl. Acad. Sci. 83: 2632-2636	-
	(198	6).		·		İ
	ROV	VE et al. J. Ge	en. Virol. 69: 1217-1228 (1988).			
		,,	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7		•	
1 .	ROV	VLINSON, et al.	., Cancer Res. 47: 6528-6531 (1	987).		
1						1
	SAB	BATINI, et al., "	'Autoantibodies from Patients wit	h Systemic Lunus Erythematosus Rind a Shan	ed Sequence of AmD and Epstein-Barr Virus-	┼
	Enco	ded Nuclear Ar	ntigen EBNA I," Eur. J. Immunol.	23:1146-1152 (1993).	ed deduction of Milb and Chaten-Ball Ands-	İ
-	040	TOT OF WAR	/ A DELIZIO			
1	SAD	ZOI-DELVAUX	(& BENTIER, 24th International I	Herpesvirus Workshop July 17-23 (Mass. Inst.	Tech.) Abst. 9.009 (1999).	
		•		•		
	SAD	ZOT-DELVAUX	, et al,. J. Immunol. 159: 2802 (1	997).		+
1 1				,		
	C41	ONIOVI -A-1	And Birth and Ass.			
	SAL	winski, et al.,	Anal. Biochem. 117: 136-146 (1	981).		T
<u></u>	_ [1
	SCH	MIDT, et al., * P	Proc. Natl. Acad. Sci. USA 88(21)	: 9478-9482 (1991).		╂
1/ 1	- 1		`,			
<u> </u>					<u> </u>	
caminers	Τ		/	Date Consider		
ignature			-	. Date Consider	8/5/05	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Include copy of this form with next communication to applicant.	Draw line through citation if not in conformance and not considered

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language

	•	ı	
-		L	

		, l			Patent and Trademark Ottob: U.S. DEPARTMENT OF COMMERC			
Under the Paper	work Reduction Act o	od 1995, no persons es	e required to respond to a collection of in	tornation untess à contains à valid OMB control number	<u></u>			
Substitute for form 1449APTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			РТО	Complet if Kn wn				
			BY APPLICANT	Application Number	Divisi nal 1 09/718,693			
	,	,	,,	Filing Date	August 22, 2003			
				First Named Inventor	John B. Harley			
				Group Art Unit				
				Examiner Name				
Sheet	13	of	15	Attorney Docket Number	OMRF 177 DIV			
			OTHER ART	NON PATENT LITERATURE DOCUM	ENTS			
Examiner's Initials*	Cite No.1			(in CAPITAL LETTERS), title of the article it, serial, symposium, catalog, etc.), date, pa				

		OTHER ART - NON PATENT LITERATURE DOCUMENTS							
Examiner's Cite No.1		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published							
A		SCOTET, et al., J. Exp. Med. 184: 1771-1780 (1996).							
		SCOTET, et al., "Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes," Eur J. Immunol. 29: 973-985 (1999).							
		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein- Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67 2253-2258 (1986).							
		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," Digestive Dis. Sci. 39:15-18 (1994).							
		SNOECK, et al., Multidisciplinary approach to understanding cytomegalovirus disease Excerpta Medica: Amsterdam, pp. 269-278 (1993).							
		SPAETE, Transplant Proc. 23: 90-96 (1991).							
11		SPIRA, et al., <i>J. Immunol. Meth.</i> 74: 307 (1984).							
+		STEPLEWSKI, et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants," Proc. Natl. Acad. Sci., USA 82: 8653-8657 (1985).							
1		STRAUS, et al., Ann. Int. Med. 108: 221 (1988).							
1/		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sciences," Ann. Neurol. 17:371-377 (1985).							

Examiner's		Date Considered 4
Signature	\sim	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

	1	ı	
•		۰	

			L	J		Approved for use direcuph 1031/99, QMB Patient and Tradement Office: U.S. DEPARTMENT OF CO	OSS 1-QUO DMOMERICA
		tion Act of 1995, no pe tute for form 14			brinsilon unless à contairs a valid OAAB control number	Complet If Kn wn	
				DISCLOSURE APPLICANT	Applicati n Number	Divisi nat 109/718,693	
		(use as man	y sheets	as necessary)			
					Filing Date	August 22, 2003	
					First Named Inventor	John B. Harley	
					Group Art Unit Examiner Name		
Sheet	 1	4 of		15	Attorney Docket Number	OMRF 177 DIV	
Onest 1	<u>_</u>	- 1. "			Attorney bocket Number	OMRE 177 DIV	
				OTHER ART N	NON PATENT LITERATURE DOCU	MENTS	
Examiner's Initials*	Cite No.1			(book, magazine, journal	(in CAPITAL LETTERS), title of the article , serial, symposium, catalog, etc.), date, p publisher, city and/or country where public	page(s), volume-issue number(s),	T
ħ		SUN, et al., Hyb	oridoma 5(S	Supp1): S17 (1986).			
		SUNDBERG, et	aL, <i>Nature</i>	e 250: 587-588 (1974).			
		TAKEI, et al., In	t. Immunol	J. 9. 739-743 (1997).			-
		TAN, Rev. Int. D	is. 1: 997-	1006 (1979).			
		TATEISHI, et al. Arthritis Rhuem.	, *Spontan 36:827-83	eous Production of Epstei 15 (1993).	n-Barr Virus by B Lymphoblastoid Cell Line	s Obtained from Patients with Sjogren's Syndrome,"	
		THORLEY-LAW	SON, et al	., *Epstein-Barr virus and (the B cell: that's all it takes," <i>Trends in Micro</i>	obiology 4(5): 204-208 (1996).	
		TODA, et al., "S Sullivan, ed.) pp	jogren's sy . 647-650 (yndrome (SS) and Epstein (Plenum Press, New York	Barr virus (EBV) reactivation," in <u>Lacrimal</u> 1994).	Gland, Tear Film, and Dry Eye Syndrome. (D.A.	
		TSAI, et al., "De Childhood Syste	tection of E mic Lupus	pstein-Barr Virus and Cyt Erythematosus," Int. Arch	omegalovirus Genome in White Blood Cells . <i>Allergy Immunol</i> . 106:235-240 (1995).	s from Patients with Juvenile Rheumatoid Arthritis and	
		VENABLES, et Exp. Immunol., 1	al., "Persis 75:359-364	tence of Epstein-Barr Viru (1989).	s in Salivary Gland Biopsies from Healthy I	ndividuals and Patients with Sjogren's Syndrome," Clin.	
		VENABLES, et a	al., "The Re	sponse to Epstein-Barr Vi	irus Infection in Sjogren's Syndrome," J. Au	toimmunity 2:439-448 (1989).	

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant to place a check mark here if English language Translation is attached.

Please	Mos a r	nde eko	(+) inside	this box

9e01) ASOSSOTY 1001-1230 EMD . CEVITOR figurate to to the vegoty 2017 ANNO TO THEMETRA GED . 2.U SCRIPT TO THE LIBITATION TO THE COMMISSION OF

					Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE	
Under the Pap	enwork Reduction Act of	1995, no persons	are required to respond to a collection of int	ortration unless il contains a valid CMB control number		
Substitute for form 1449A/PTO				Complete if Kn wn		
	STATE	MENT	N DISCLOSURE BY APPLICANT	Applicati n Number	Divisi nat 1 09/718,693	
(use as many sheets as necessary)				Filing Date	August 22, 2003	
				First Named Inventor	John B. Harley	
				Group Art Unit		
				Examiner Name		
Sheet	15	of	15	Attorney Docket Number	OMRF 177 DIV	

		OTHER ART NON PATENT LITERATURE DOCUMENTS						
Examiner's Initials*	Cite No. ¹							
AJ		VENABLES, et al., Arthr. Rheum. 24: 1459-1468 (1981).						
		VRISENDORP, et al., "Radioimmunoglobulin therapy" in <u>High Dose Cancer Therapy</u> (Armitage, et al. eds) Williams & Wilkins: Baltimore, pp. 84-123 (1992). WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," <i>Drugs</i> 47:153-205 (1994).						
		WANG, et al., Radial. Res. 141; 292-302 (1995).						
	-	WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," Med. Hypotheses 25:93-97 (1988).						
		WATSON, et al., "Certain Properties Make Substances Antigenic," in Molecular Biology of the Gene, Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).						
		WHITLEY, "Herpes Simplex viruses" in <u>Field's Virology</u> Lippincott-Raven, pp. 2297-2330 (1996).						
			<u> </u>					
L		L	Ц					

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner's Signature

¹ Unique citation designation number ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁸ Applicant to place a check mark here if English language Translation is attached.